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Calcineurin inhibitors enhance low-density lipoprotein oxida- complexes with their respective immunophilins and
tion in transplant patients. these complexes then inhibit a key enzyme serine/threo-
Background. Our objective was to assess the pro-oxidant nine phosphatase, calcineurin, which is involved in thestatus of neoral and tacrolimus in renal transplant patients and
dephosphorylation of the transcription factor NFA-T.monitor the protection provided by vitamin C and vitamin E
in normalizing low density lipoprotein (LDL) oxidation lag Calcineurin-mediated dephosphorylation of NFA-T is a
time of tacrolimus-treated patients. pivotal step in the transcription and translation of the
Methods. Plasma LDL was isolated by density gradient ul- IL-2 gene. The susceptibility of low density lipoprotein
tracentrifugation from renal transplant patients receiving neo-
(LDL) to oxidation is increased by cyclosporine (CsA)ral, tacrolimus and tacrolimus with vitamin C and vitamin E.
[2, 3]. Oxidized LDL (Ox-LDL) may be of critical impor-Oxidation was initiated by the addition of CuCl2 at 378C and
monitored at 234 nm over 480 minutes and oxidation lag time tance in triggering a cascade of cellular processes that
was computed. Total antioxidant capacity of serum was mea- leads to the formation of fatty streak and eventually
sured using the enhanced chemiluminescent method.
atherosclerotic lesions in the artery wall [4, 5]. The sus-Results. LDL from tacrolimus-treated patients had signifi-
ceptibility of LDL to oxidize can be determined in vitrocantly lower oxidation lag time and serum antioxidant activity
in comparison with neoral-treated patients, and this was partic- [6] and the lag phase (the time elapsed before the oxida-
ularly significant during the first four months after transplanta- tion chain reaction starts) has been found to correlate
tion. Vitamin C and E supplementation in tacrolimus treated with the extent of atherosclerosis in patients with coro-patients provided protection against oxidation and normalized
nary artery disease. Previously such studies were donetheir oxidation lag time.
in Sandimmune (CsA)-treated renal transplant patientsConclusion. Calcineurin-inhibiting drugs, CsA and tacroli-
mus, have pro-oxidant activity and they increase the suscepti- [2, 3]. Therefore, a pilot study [7] was undertaken to
bility of LDL to oxidation. Neoral formulation is fortified with compare the ability of LDL collected from neoral- (N 5
DL-a tocopherol and therefore provides protection against
23) and tacrolimus-treated renal transplant patients (N 5oxidation. The present study clearly demonstrates the benefit
10) to oxidize with the ability of LDL obtained fromof giving vitamin C and E supplements to patients taking tacro-
limus and this seems to be particularly important during the normal subjects (N 5 15) to oxidize. This study estab-
early period after transplantation. lished that the LDL oxidation lag time of neoral-treated
patients were comparable to normal subjects and the
difference between our results and those previously pub-
The potential causes of hyperlipidemia in renal trans- lished for Sandimmune treated patients [2, 3] were due
plantation include dietary indiscretion and the use of to the fortification of neoral formulation with DL-a to-
atherogenic immunosuppressive drugs; it is possible to copherol. LDL collected from tacrolimus patients had
ascribe an hierarchical status for the atherogenicity of significantly lower oxidation lag time in comparison with
immunosuppressive drugs: steroids . cyclosporine . sir- neoral-treated patients. There was also a significant de-
olimus . tacrolimus . azathioprine . mycophenolate ficiency of total serum antioxidant concentration in ta-
mofetil [1]. The interleukin-2 (IL-2) inhibiting immuno- crolimus-treated patients. These findings suggest a proxi-
suppressive drugs, cyclosporine and tacrolimus form dant status for calcineurin-inhibiting drugs. Therefore,
the present study was undertaken to compare the ability
of LDL from tacrolimus-treated renal transplant patientsKey words: cyclosporine, neoral, tacrolimus, oxidation, renal trans-
plantation. to oxidize before and after giving them with vitamin E
and C supplements. 1999 by the International Society of Nephrology
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Table 1. Demographic data and results
Tacrolimus Tacrolimus Tacrolimus at 24 months
at 4 months at 23 months after vitamin supplementation
(I) (II) (III) P value
Male 8 10
Female 2 10
Age mean years 6 sd 5569 48612 NS
Duration of treatment months 464 2365 24
Trough whole blood Tacrolimus level ng/ml 8.762.7 6.560.5 6.460.5 NS
Serum creatinine lmol/liter 166675 184621 177617 NS
Serum urea mmol/liter 13.268.1 14.161.8 12.461.5 NS
Serum cholesterol mmol/liter 5.7761.11 5.260.2 4.960.2 NS
Serum triglyceride mmol/liter 2.6960.73 2.7160.4 2.2860.2 NS
LDL oxidation lag time min 45.1616 56.563 77.365 ,0.03 (I vs. II)
,0.02 (II vs. III)
Total serum AOX lmol trolox Eq/liter 283677 504647 623667 ,0.001 (I vs. II)
,0.006 (II vs. III)
METHODS jugated diene formation at l 5 234 nm. In a pilot study
involving 23 neoral-treated and 10 tacrolimus-treatedPatients
patients, there was a significant difference between the
We studied the oxidizability of LDL from 20 stable mean oxidation lag times (neoral 67.5 6 2.5 min and
kidney transplant patients (10 female, 10 male, with a tacrolimus 45.1 6 16 min, P , 0.002). The total antioxi-
mean age of 48 6 12 years) treated with tacrolimus dant concentration, measured as micromoles per liter
before and four weeks after giving vitamin C 500 mg of trolox equivalent (283 6 77), was significantly lower
b.i.d. together with vitamin E 200 mg b.i.d. These patients (P , 0.03) in tacrolimus-treated in comparison with neo-
were also treated with steroids and azathioprine and ral-treated patients (368 6 22).
had been transplanted for 23 6 5 months. None of the However, the tacrolimus-treated patients had been
patients in the study were taking lipid-lowering drugs transplanted for a shorter period of time (4 6 4 months)
before or during the study nor antioxidants before the compared with neoral-treated patients (94 6 43 months),
study. and this difference was significant (P , 0.001). There-
Serum cholesterol, triglycerides and renal function fore, we selected a group of patients who had been on
tests were carried out on blood samples collected at 12 tacrolimus for a relatively longer period of time (23 6
hours after taking tacrolimus or tacrolimus with vitamins 5 months) for the vitamins C and E supplementation
study. Before vitamin supplementation the mean oxida-C and E using standard methods on a Hitachi 747 ana-
tion lag time was 56.5 6 3 minutes, and there was alyzer. Whole blood (EDTA) tacrolimus levels were mea-
significant improvement in the mean oxidation lag timesured using IMX Tacrolimus II assay (Abbott Diagnos-
measured four weeks after starting vitamin supplementa-tics, Maidenhead, Berskshire, UK). LDL oxidizabilty
tion (77.3 6 5.1 min, P , 0.02). The mean total antioxi-was measured the method of McDowell et al [7, 8]. Total
dant concentration also increased significantly (P ,antioxidant capacity of serum was measured using the
0.006) from 504 6 47 mmol/liter before vitamin supple-enhanced chemiluminescent method [7, 9].
mentation to 623 6 67 mmol/liter after vitamin supple-
mentation. However, it is important to note that thereStatistics
was an improvement in the mean oxidation lag timeData are presented as means 6 standard error of
with time after transplantation in the tacrolimus-treatedmeans (sem) and were tested for statistical significance
patients even before starting vitamin supplementationusing the unpaired (group I vs. group II) and paired
(45.1 6 16 at 4 months to 56.5 6 3 at 23 months, P ,
(group II vs. group III) Student’s t-test. A P-value of 0.03). This could be due to general improvement in the
,0.05 was considered significant. nutritional status of patients and this was reflected in
their total serum antioxidant measurements, which rose
from 283 6 77 to 504 6 47 mmol/liter, P , 0.001; Fig. 1).RESULTS
Demographic data and quantitative results are given
DISCUSSIONin Table 1.
The susceptibility of LDL to copper-induced oxidation Studies into macrovascular disease have highlighted
the role of oxidation of plasma lipoproteins as well aswas continuously monitored by the measurement of con-
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separated from patients taking neoral, a new formulation
of CsA with the addition of DL-a tocopherol, did not
show an increased susceptibility to copper induced LDL
oxidation [7]. The increased susceptibility reported [7]
in tacrolimus-treated patients was thought to be due
to the decreased antioxidant activity. With time after
transplantation antioxidant activity increased in patients
taking tacrolimus, so the susceptibility to oxidation de-
creased. A protective role for antioxidants in large-vessel
disease has been postulated [18], and Rabl et al demon-
strated that antioxidant treatment with vitamins could
be important in reducing reperfusion damage in renal
transplantation [19]. Therefore, the present short-term,
limited study demonstrates the benefit of giving vitamin
C and E supplements to patients taking tacrolimus, andFig. 1. Low density lipoprotein (LDL) oxidation curves of tacrolimus
this is particularly important during initial stages of trans-treated patients. LDL was isolated from the blood of tacrolimus treated
patients . 12 hours post-dose, before (s) and one month after (,) plantation when there is an adequate intake of antioxi-
taking vitamin E and C supplements. Oxidation of LDL (50 mg/l) dants.was initiated by adding Cu21 (2 mmol/liter) and oxidation monitored
continuously by recording the absorbance at l 5 234 nm. Lag times
Reprint requests to Dr. Zac Varghese, Renal Research Laboratory,were calculated as described in the Methods section. The graph shows
Center for Nephrology, Royal Free and UCL School of Medicine, Pondthe mean oxidation curves of 20 patients before (s) and after (,)
Street, London NW3 2QG, England, United Kingdom.vitamin E and C treatment.
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